Actually I noticed that the price in India was only discounted by 20%.
I also remember that it was Swami's knowledge and contacts that have accelerated the BARDA trial completion which will undoubtedly bring substantial revenue benefits in due course and the abandonment of Diabetic foot ulcer trial may have changed the plans that he had. Now maybe there were other philosophical differences in the strategy for the company's future or where he resided but I think he deserves due credit.
Actually I noticed that the price in India was only discounted...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.22 |
Change
0.015(1.24%) |
Mkt cap ! $842.8M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.22 | $1.19 | $2.606M | 2.146M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 37701 | $1.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 102533 | 4 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| PNV (ASX) Chart |